Cell News and Research

RSS

Differences between therapeutic radiation therapy and exposure to excessive nuclear plant fallout radiation

"The Canadian Association of Radiation Oncology (http://www.caro-acro.ca) is the voice for specialists in Canada who treat patients' cancer with radiation. In that capacity," explains Dr. Matthew Parliament, president of CARO-ACRO, "we work with proven, controlled, targeted application of various forms of radiation therapy to treat and cure cancer."

21 Mar 2011

China PharmaHub, University of California enter license agreement for stem cell universal donor blood product

China PharmaHub Corp., a biopharmaceutical acquisition and development company, today announced that it has signed a exclusive worldwide license agreement with the University of California, for worldwide rights to develop, commercialize and market a universal donor blood product derived from embryonic stem cells developed by UCSD Associate Professor of Medicine and Pediatrics Dr. Ewa Carrier.

21 Mar 2011

Study unravels molecular mechanism of biomolecule RNA that plays dynamic regulatory role in protein selection

If a big bunch of your brain cells suddenly went rogue and decided to become fat cells, it could cloud your decision-making capacity a bit. Fortunately, early in an organism's development, cells make firm and more-or-less permanent decisions about whether they will live their lives as, say, skin cells, brain cells or, well, fat cells.

21 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer.

21 Mar 2011

WaferGen, NuGEN collaborate to develop integrated workflows for gene expression profiling and target enrichment

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, and NuGEN Technologies, Inc., a leader in innovative genomic samples preparation, today announced they will co-develop and co-market simple, seamlessly integrated workflows for gene expression profiling and target enrichment to enable researchers to more easily achieve high-throughput, high-density real-time PCR with small, degraded, and hard-to-replace clinical specimens, such as formalin fixed paraffin embedded tissue (FFPE).

21 Mar 2011

Finesse launches new core modules for off-line data processing in fourth generation TruBio DV software

Finesse Solutions, LLC, a manufacturer of measurement and control solutions for life science process applications, has announced the official launch of two new core modules for off-line data processing in its fourth generation TruBio DV software. These modules are targeted at enabling bioprocessing specialists to manage data from third party equipment and process analyzers, and obtain automated electronic records of their batch.

21 Mar 2011

Research outlines how cilia disease gene products regulate early cilium formation

An international collaboration jointly led by University College Dublin, University of Alabama and Simon Fraser University, British Columbia has outlined in the Journal of Cell Biology how cilia disease gene products regulate important aspects of early cilium formation and the integrity of the ciliary transport gate.

21 Mar 2011

Advanced Cell Technology reduces 2010 debt to less than $1 million

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today 2010 year-end results for the period ended December 31, 2010. The Company utilized $8.8 million in cash for operations during the year, compared to $5.1 million in the year-earlier period.

21 Mar 2011

Life Technologies enters clinical trials for DNA SBT platform for analysis of Human Leukocyte Antigen system

Life Technologies Corporation today announced that it is the first life science tools provider entering clinical trials to prove the safety and effectiveness of their DNA sequence-based typing (SBT) platform for analysis of the Human Leukocyte Antigen (HLA) system. Submission for 510(k) clearance of this SBT platform will follow completion of the clinical trials, which is anticipated this summer.

21 Mar 2011

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

XenoPort, Inc. announced today preliminary top-line results from a Phase 2b clinical trial of arbaclofen placarbil (also known as AP) as adjunctive therapy in patients with gastroesophageal reflux disease (GERD) who do not experience complete relief of GERD symptoms while being treated with proton pump inhibitors (PPI).

21 Mar 2011

More opportunities to develop therapies for protein misfolding

Romping clumps of misfolded proteins are prime suspects in many neurological disorders including Alzheimer's, Parkinson's, and Creutzfeld-Jakob Disease. Those diseases are devastating and incurable, but a team of biologists at Brown University reports that cells can fix the problems themselves with only a little bit of help. The insight suggests that there are more opportunities to develop a therapy for protein misfolding than scientists had thought.

21 Mar 2011

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

21 Mar 2011

Almac, Exco InTouch enter exclusive integrated patient management alliance

The Almac Group and Exco InTouch announced today that Almac's Clinical Technologies business unit, the leading provider of IXRS(R) (Interactive Voice and Web Response) services relating to patient and drug supply management, has formed an exclusive integrated patient management alliance with Exco InTouch, an innovative firm specializing in patient recruitment, retention, compliance and ePRO services.

21 Mar 2011

New synchrotron-based imaging technique offers more detailed chemical images

With intensity a million times brighter than sunlight, a new synchrotron-based imaging technique offers high-resolution pictures of the molecular composition of tissues with unprecedented speed and quality. Carol Hirschmugl, a physicist at the University of Wisconsin-Milwaukee (UWM), led a team of researchers from UWM, the University of Illinois at Urbana-Champaign and University of Illinois at Chicago (UIC) to demonstrate these new capabilities.

21 Mar 2011

Smoking during pregnancy increases risk of children becoming smokers too

New research has revealed that prenatal exposure to nicotine increases the vulnerability to nicotine self-administration in adolescent mice. The results support the hypothesis that adolescents with prenatal nicotine exposure are more likely to start smoking earlier than their peers and that they are also more susceptible to the addictive effects of nicotine, especially as a result of stress and peer pressure.

21 Mar 2011

Researchers discover 'broad spectrum' cancer suppressor gene

Portuguese researchers have discovered a "broad spectrum" cancer suppressor gene - called LRP1B - which acts by removing proteins crucial for cancer development from the tumour environment. The fact that LRP1B does not act on the tumour itself (in this study thyroid tumours) but, instead, on molecules which are known to be important to many different cancers is what makes it so interesting.

21 Mar 2011

$CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma$

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

Cell Therapeutics, Inc. today announced that it has initiated its randomized pivotal trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL").

21 Mar 2011

Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint

Genentech, a member of the Roche Group, today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.

21 Mar 2011

CAPCC, Health Canada, Safe Kids Canada remind parents about dangers of unintentional poisoning

Kathleen Wong was frantic when her three-year-old daughter Kiana took a nibble from one of her grandfather's diabetes tablets. "We were visiting my father and he had put his medication out on the counter to take later," recalls Kathleen. "My daughter got up on a chair near the counter and took a bite of one of the pills."

19 Mar 2011

Cell News and Research

Differences between therapeutic radiation therapy and exposure to excessive nuclear plant fallout radiation

China PharmaHub, University of California enter license agreement for stem cell universal donor blood product

Study unravels molecular mechanism of biomolecule RNA that plays dynamic regulatory role in protein selection

Sarsia Seed provides follow-up funding for APIM Therapeutics

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

WaferGen, NuGEN collaborate to develop integrated workflows for gene expression profiling and target enrichment

Finesse launches new core modules for off-line data processing in fourth generation TruBio DV software

Research outlines how cilia disease gene products regulate early cilium formation

Advanced Cell Technology reduces 2010 debt to less than $1 million

Life Technologies enters clinical trials for DNA SBT platform for analysis of Human Leukocyte Antigen system

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

More opportunities to develop therapies for protein misfolding

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Almac, Exco InTouch enter exclusive integrated patient management alliance

New synchrotron-based imaging technique offers more detailed chemical images

Smoking during pregnancy increases risk of children becoming smokers too

Researchers discover 'broad spectrum' cancer suppressor gene

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint

CAPCC, Health Canada, Safe Kids Canada remind parents about dangers of unintentional poisoning

What are the challenges of cell line development? eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics